Seed Innovations Limited Investee Company Update: Little Green Pharma Ltd
07 Setembro 2023 - 6:40AM
RNS Non-Regulatory
TIDMSEED
Seed Innovations Limited
07 September 2023
7 September 2023
SEED Innovations Limited
("SEED" or the "Company")
Investee Company Update: Little Green Pharma Ltd
SEED Innovations Ltd, the AIM-quoted company investment company
providing shareholders with exposure to early-stage health,
wellness and medical cannabis companies to which, in normal
circumstances, they have limited access to, is pleased to note an
announcement released on the ASX by its portfolio company, Little
Green Pharma Ltd ('LGP').
The Company owns 7,324,796 ordinary shares in LGP representing
2.44% of LGP's issued share capital.
The following announcement, which was released on the ASX is set
out without any material changes.
Large Scale Cannabis Study Findings Released
Results find medicinal cannabis significantly improves pain,
quality of life & fatigue.
Little Green Pharma (ASX: LGP) wishes to advise of a media
release issued today relating to the analysis of the initial three
month results from the QUEST Initiative[1] . A copy of that media
release is appended to this link:
https://investor.littlegreenpharma.com/site/pdf/f8a54588-1827-47b7-a13e-499fc99d6909/Large-scale-cannabis-study-findings-released.pdf
Analysis of the initial three-month follow-up results from 2,327
Australian patients participating in the QUEST Initiative show:
-- very strong evidence of clinically meaningful improvements
for those suffering health-related quality of life (HRQL) and
fatigue
-- clinically meaningful reductions in pain and significant
improvements for moderate-severe anxiety and depression
Analysis of 12-month results is currently being undertaken to
see if such improvements are maintained over the longer term.
Overview
The QUEST Initiative, sponsored by LGP, was one of the world's
largest longitudinal clinical studies investigating the effect of
medicinal cannabis on patient quality of life and health economic
impacts. The study was led by a leading Australian university with
LGP exclusively supplying the medicinal cannabis products to
patients enrolled in the study and with Study costs fully funded
from patient participation fees. The study was also supported by
not-for-profit private health insurance provider Health Insurance
Fund of Australia (HIF) and guided by an experienced advisory group
and endorsed by a range of national bodies, such as MS research
Australia, Chronic Pain Australia, Arthritis Australia and Epilepsy
Australia. For a full analysis of the results, please refer to the
link attached.
The announcement in full can be accessed from the following
link:
https://investor.littlegreenpharma.com/site/pdf/f8a54588-1827-47b7-a13e-499fc99d6909/Large-scale-cannabis-study-findings-released.pdf
- Ends -
For further information on the Company please visit:
www.seedinnovations.co or contact:
Ed McDermott SEED Innovations Ltd E: info@seedinnovations.co
Lance de Jersey
James Biddle Beaumont Cornish Limited, T: (0)20 7628 3396
Roland Cornish Nomad
------------------------- ------------------------------
Isabella Pierre Shard Capital Partners T: (0)20 7186 9927
Damon Heath LLP
Broker
------------------------- ------------------------------
Catherine Leftley St Brides Partners Ltd, E: info@stbridespartners.co.uk
Ana Ribeiro Financial PR
Isabelle Morris
------------------------- ------------------------------
Notes
Seed Innovations Ltd
SEED Innovations is an AIM quoted investment company focused
primarily on disruptive high growth life sciences and technology
businesses particularly within the medical cannabis arena. The
Company's strategy is to identify early-stage opportunities that
have an upcoming investment catalyst and grow its portfolio in
terms of value whilst limiting the number of investee companies to
a level where relevant time can be devoted to each.
About Little Green Pharma
Little Green Pharma is a global, vertically integrated and
geographically diverse medicinal cannabis business with operations
from cultivation and production through to manufacturing and
distribution.
The Company has two global production sites for the manufacture
of its own-branded and white-label ranges of GMP-grade medicinal
cannabis products, being a 21,500m2 cultivation and 4,000m2 GMP
manufacturing facility capable of producing over 30 tonnes of
medicinal cannabis biomass per annum located in Denmark (EU) and an
indoor cultivation and manufacturing facility located in Western
Australia capable of producing 3 tonnes of medicinal cannabis
biomass per annum.
Little Green Pharma products comply with all required Danish
Medicines Agency and Therapeutic Goods Administration regulations
and testing requirements. With a growing range of products
containing differing ratios of active ingredients, Little Green
Pharma supplies medical-grade cannabis products to Australian,
European and overseas markets.
The Company has a strong focus on patient access in the emerging
global medicinal cannabis market and is actively engaged in
promoting education and outreach programs, as well as participating
in clinical investigations and research projects to develop
innovative new delivery systems.
[1] Refer to ASX announcement dated 18 February 2021.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUPUQWBUPWUBM
(END) Dow Jones Newswires
September 07, 2023 05:40 ET (09:40 GMT)
Fastforward Innovations (LSE:FFWD)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Fastforward Innovations (LSE:FFWD)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
